Press release
CARsgen Announced 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR
About this update from Moderna, Inc.
[{"type":"text","content":"SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results.\nBusiness Highlights\nZevorcabtagene autoleucel (CT053) NDA was approved by the NMPA.Satricabtagene autoleucel (CT041) IND was approved by the NMPA for the postoperative adjuvant therapy of Claudin18.2 positive pancreatic cancer.CT011 IND was approved by the NMPA for GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection.Two hepatocellular carcinoma patients treated with a combination of local therapy and GPC3 CAR-T cells achieved disease-free survival exceeding 7 years.CT071 IND was cleared by the FDA for relapsed/refractory multiple myeloma and relapsed/refractory primary plasma cell leukemia.Developed a proprietary CARcelerateTM platform, shortening the manufacturing time to around 30 hours. The platform has been utilized for CT071.CARsgen and Huadong Medicine entered into a collaboration agreement for the commercialization of zevorcabtagene autoleucel in mainland China.CARsgen and Moderna initiated a collaboration agreement to investigate satricabtagene autoleucel in combination with an mRNA cancer vaccine.Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, \"In 2023, CARsgen remained dedicated to our vision, 'Making Cancer Curable' and were committed to reinforcing our team and improving operational efficiency. We made substantial progresses in the regulatory and clinical development of our innovative products and the advancement of new technology platforms. Multiple important milestones for different product candidates across clinical, regulatory, and business development were achieved. We are optimistic that we will navigate and overcome the challenges ahead with resilience and determination, advancing our innovative cell therapies.\"\n\nZevorcabtagene autoleucel (CT053) is an autologous fully human CAR T-cell product candidate against B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM). As informed by the NMPA on March 1, 2024, zevorcabtagene autoleucel was granted conditional approv...